Last reviewed · How we verify
Rilzabrutinib crystalline form
Rilzabrutinib crystalline form is a Small molecule drug developed by Sanofi. It is currently in Phase 1 development. Also known as: SAR444671.
At a glance
| Generic name | Rilzabrutinib crystalline form |
|---|---|
| Also known as | SAR444671 |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rilzabrutinib crystalline form CI brief — competitive landscape report
- Rilzabrutinib crystalline form updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Rilzabrutinib crystalline form
What is Rilzabrutinib crystalline form?
Rilzabrutinib crystalline form is a Small molecule drug developed by Sanofi.
Who makes Rilzabrutinib crystalline form?
Rilzabrutinib crystalline form is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is Rilzabrutinib crystalline form also known as anything else?
Rilzabrutinib crystalline form is also known as SAR444671.
What development phase is Rilzabrutinib crystalline form in?
Rilzabrutinib crystalline form is in Phase 1.
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: SAR444671
- Compare: Rilzabrutinib crystalline form vs similar drugs
- Pricing: Rilzabrutinib crystalline form cost, discount & access